BTIG Research downgraded Avita Medical from Buy to Neutral
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/20/2025 | Sell → Neutral | BTIG Research | |
| 8/8/2025 | $3.00 | Neutral → Sell | BTIG Research |
| 12/24/2024 | $25.00 | Buy | D. Boral Capital |
| 4/11/2024 | Buy → Neutral | BTIG Research | |
| 6/27/2023 | $23.00 | Overweight | Cantor Fitzgerald |
8-K - AVITA Medical, Inc. (0001762303) (Filer)
8-K - AVITA Medical, Inc. (0001762303) (Filer)
10-Q - AVITA Medical, Inc. (0001762303) (Filer)
VALENCIA, Calif., Jan. 13, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. ((ASX: AVH, NASDAQ:RCEL), a leading therapeutic acute wound care company delivering transformative solutions, today announced unaudited preliminary financial results and a business update for the fourth quarter and fiscal year 2025. The Company also provided its preliminary outlook for fiscal year 2026, ahead of its presentation at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026 at 5:15 p.m. Pacific Time (Thursday, January 15, 2026, at 12:15 p.m. Australian Eastern Daylight Time). The webcast can be accessed through AVITA Medical's website at: https://ir.avitamedical.com/events-and-presentations
Veteran healthcare executive Joe Woody joins the BoardLou Panaccio retires after over a decade of service VALENCIA, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. ((ASX: AVH, NASDAQ:RCEL), a leading therapeutic acute wound care company delivering transformative solutions, today announced the appointment of Joe Woody as a new non-executive Director and the retirement of Lou Panaccio, who served as Chairman from July 2014 to August 2025. "We are pleased to welcome Joe to the Board. His extensive track record leading global med-tech companies and driving commercial excellence will be invaluable as we continue to scale AVITA Medical's growth," said Cary Vance, Interim CEO of
VALENCIA, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. ((ASX: AVH, NASDAQ:RCEL), a leading therapeutic acute wound care company delivering transformative solutions, today announced that Cary Vance, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 5:15 p.m. Pacific Time. A live audio webcast of the presentation will be accessible under the Events & Presentations section of AVITA Medical's website at https://ir.avitamedical.com/events-and-presentations. A replay of the webcast will be available following the conclusion of the event. About AVITA Medical, Inc. AVITA Medical® is a leading therapeut
4 - AVITA Medical, Inc. (0001762303) (Issuer)
4 - AVITA Medical, Inc. (0001762303) (Issuer)
4 - AVITA Medical, Inc. (0001762303) (Issuer)
BTIG Research upgraded Avita Medical from Sell to Neutral
BTIG Research downgraded Avita Medical from Neutral to Sell and set a new price target of $3.00
D. Boral Capital initiated coverage of Avita Medical with a rating of Buy and set a new price target of $25.00
4 - AVITA Medical, Inc. (0001762303) (Issuer)
4 - AVITA Medical, Inc. (0001762303) (Issuer)
4 - AVITA Medical, Inc. (0001762303) (Issuer)
Veteran healthcare executive Joe Woody joins the BoardLou Panaccio retires after over a decade of service VALENCIA, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. ((ASX: AVH, NASDAQ:RCEL), a leading therapeutic acute wound care company delivering transformative solutions, today announced the appointment of Joe Woody as a new non-executive Director and the retirement of Lou Panaccio, who served as Chairman from July 2014 to August 2025. "We are pleased to welcome Joe to the Board. His extensive track record leading global med-tech companies and driving commercial excellence will be invaluable as we continue to scale AVITA Medical's growth," said Cary Vance, Interim CEO of
Board Chairman Cary Vance appointed Interim CEOBoard member Jan Stern Reed appointed Lead Independent DirectorThird quarter 2025 preliminary revenue expected to be approximately $17 million VALENCIA, Calif., Oct. 16, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH)) ("AVITA Medical", or the "Company"), a leading therapeutic acute wound care company, today announced that the Board of Directors has named Chairman of the Board Cary Vance as Interim Chief Executive Officer, effective immediately. In conjunction with this appointment, Jim Corbett is leaving his positions as CEO and member of the Board. Mr. Vance will continue to serve as Chairman of the Board, while Board m
Dr. Tarnoff brings extensive executive and medical leadership experience from various organizations, including Tufts Medical Center and Medtronic.The Board thanks Lou Panaccio, its long-standing Board Chair, for his service as he steps down and Cary Vance assumes the Chair position. VALENCIA, Calif. and MELBOURNE, Australia, Aug. 06, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH)), a leading therapeutic acute wound care company delivering transformative solutions, announced today the appointment to its Board of Directors (the "Board") of Michael Tarnoff, MD, FACS, as a non-executive Director, effective August 6, 2025. Dr. Tarnoff's appointment comes as the Company fu
VALENCIA, Calif., Jan. 13, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. ((ASX: AVH, NASDAQ:RCEL), a leading therapeutic acute wound care company delivering transformative solutions, today announced unaudited preliminary financial results and a business update for the fourth quarter and fiscal year 2025. The Company also provided its preliminary outlook for fiscal year 2026, ahead of its presentation at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026 at 5:15 p.m. Pacific Time (Thursday, January 15, 2026, at 12:15 p.m. Australian Eastern Daylight Time). The webcast can be accessed through AVITA Medical's website at: https://ir.avitamedical.com/events-and-presentations
VALENCIA, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH)), a leading therapeutic acute wound care company delivering transformative solutions ("AVITA Medical," or the "Company"), today reported financial results for the third quarter ended September 30, 2025. Financial Results Commercial revenue of $17.1 million, representing a 13% decrease compared to the same period in 2024.Cash, cash equivalents, and marketable securities totaled $23.3 million as of Sept. 30, 2025.Operating expenses decreased by 24%, or $7.2 million, to $23.0 million, compared with $30.2 million in the corresponding period last year, as the Company continues to streamline operat
VALENCIA, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH)) ("AVITA Medical," or the "Company"), a leading therapeutic acute wound care company delivering transformative solutions, today announced that it will report its third quarter 2025 financial results after the close of the U.S. financial markets on Thursday, November 6, 2025. AVITA Medical will host a conference call and webcast that day at 1:30 p.m. Pacific Time (Friday, November 7, 2025, at 8:30 a.m. Australian Eastern Daylight Time) to discuss its financial results and recent business highlights. The live webcast will be accessible under the Events & Presentations section of the AVITA Medical
SC 13G - AVITA Medical, Inc. (0001762303) (Subject)
SC 13G - AVITA Medical, Inc. (0001762303) (Subject)
SC 13G/A - AVITA Medical, Inc. (0001762303) (Subject)